A detailed history of Everence Capital Management Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Everence Capital Management Inc holds 75,780 shares of BMY stock, worth $4.03 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
75,780
Previous 83,350 9.08%
Holding current value
$4.03 Million
Previous $4.52 Million 26.33%
% of portfolio
0.23%
Previous 0.3%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 03, 2024

SELL
$40.25 - $52.99 $304,692 - $401,134
-7,570 Reduced 9.08%
75,780 $3.33 Million
Q4 2023

Jan 30, 2024

BUY
$48.48 - $57.85 $699,275 - $834,428
14,424 Added 20.93%
83,350 $4.28 Million
Q3 2023

Oct 16, 2023

BUY
$57.89 - $64.73 $339,814 - $379,965
5,870 Added 9.31%
68,926 $4 Million
Q1 2023

Apr 04, 2023

SELL
$65.71 - $74.53 $358,776 - $406,933
-5,460 Reduced 7.97%
63,056 $4.37 Million
Q4 2022

Jan 31, 2023

SELL
$68.48 - $81.09 $50,606 - $59,925
-739 Reduced 1.07%
68,516 $4.93 Million
Q1 2022

Apr 11, 2022

BUY
$61.48 - $73.72 $303,096 - $363,439
4,930 Added 7.66%
69,255 $5.06 Million
Q4 2021

Jan 28, 2022

BUY
$53.63 - $62.52 $379,164 - $442,016
7,070 Added 12.35%
64,325 $4.01 Million
Q4 2020

Feb 01, 2021

SELL
$57.74 - $65.43 $69,865 - $79,170
-1,210 Reduced 2.07%
57,255 $3.55 Million
Q3 2020

Feb 01, 2021

BUY
$57.43 - $63.64 $379,612 - $420,660
6,610 Added 12.75%
58,465 $3.53 Million
Q4 2019

Jan 28, 2020

BUY
$49.21 - $64.19 $563,798 - $735,424
11,457 Added 28.36%
51,855 $3.33 Million
Q1 2019

May 06, 2019

BUY
$45.12 - $53.8 $156,566 - $186,686
3,470 Added 9.4%
40,398 $1.93 Million
Q4 2017

Feb 02, 2018

SELL
$59.94 - $65.35 $54,905 - $59,860
-916 Reduced 2.42%
36,928 $2.26 Million
Q3 2017

Oct 31, 2017

BUY
$55.23 - $63.74 $2.09 Million - $2.41 Million
37,844
37,844 $2.41 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Everence Capital Management Inc Portfolio

Follow Everence Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Everence Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Everence Capital Management Inc with notifications on news.